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Background
Up to ~40 % of Hodgkin and non-Hodgkin lymphomas
carry the Epstein-Barr virus (EBV) genome and express
type 2 viral latency proteins (T2LPs) EBNA-1, LMP-1,
LMP-2 and BARF-1. EBV specific T cells (EBVSTs) can
be generated from the blood of EBV+ individuals, but
are usually dominated by T cells specific for viral pro-
teins not expressed in type 2 latency lymphomas
(T2LPs).
Methods
To overcome this problem, we used dendritic cells,
pulsed with overlapping peptide libraries (pepmixes)
spanning T2LPs in the presence of IL-4 and IL-7 to sti-
mulate patient peripheral blood mononuclear cells.
Responder T cells were then expanded using pepmix-
pulsed, autologous activated T cells and HLA-negative
K562 cells expressing co-stimulatory transgenes.
Results
Although T2LP-specific EBVSTs could be generated
from healthy-donors, we were unable to consistently
generate EBVSTs with significant T2LP specificity from
patients. We hypothesized that patient T cells were
anergic to antigen expressed within tumors, and since
IL-15 has been shown to rescue tolerant or anergic
T cells, we replaced IL-4 with IL-15 (in combination
with IL-7). This improved antigen specificity up to
10-fold. Further dose optimization showed significant
advantages in cytolytic activity, proliferation and antigen
specificity with higher dose of IL-15. We achieved
higher fold expansion (3 fold mean increase in absolute
EBVST numbers) and enhanced specificity for T2LPs
(high vs. low IL-15 concentration: EBNA1: 156±218
vs. 13±33, LMP-1: 130±223 vs. 33±68, LMP-2: 518±466
vs. 88±122 and BARF-1: 109±147 vs. 24±40; SFC/105
cells; n=11). High dose IL-15 also increased the fre-
quency of central memory T cells in the final T cell pro-
duct (36.81±17 vs. 19.09±13 % vs.13.81±22 % (IL-15 Hi
vs. IL-15 Lo vs. IL-4) in combination with Il-7).
EBVSTs manufactured using all three conditions were
used to treat 20 patients with multiply relapsed, EBV-
positive lymphoma; as adjuvant therapy after stem cell
transplantation or chemotherapy in 9 patients and as
treatment for disease in 11 patients. All patients in
remission at the time of infusion, remain in remission.
Of patients with active disease at the time of infusion,
there was one stable disease among 4 patients who
received IL-4/7-expanded T cells, one PR and one CR in
3 patients who received low does IL-15/7-expanded
T cells and two CRs and one PR among 4 patients
whose T cells were expanded in high dose IL-15 (one is
too early to assess).
Conclusions
Our results suggest that a high frequency of antigen-
specific T cells in the infused product is critical for clin-
ical activity and strategies to further improve specificity
will enhance overall tumor responses.
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